Correction to: Leukemia (2016) 30, 1126–1132; doi:10.1038/leu.2015.360
Following the publication of this Article, the authors noted that there were errors in Tables 2 and 4. The correct tables are provided below—amended values highlighted in bold and italicised.
Table 2.
Clinical characteristics, molecular analysis and constitutional symptoms of patients with essential thrombocythemia (ET) at presentation and treatment according to applied diagnostic criteria
| BCSH-defined ET (criteria A1–A3) 1,2 | WHO-defined ET criteria 3 | P-value | |
|---|---|---|---|
| General characteristics | |||
| n | 238 | 232 | |
| Age at diagnosis (years) | 61.3 (18.8–88.8) | 57.2 (17.5–88.8) | 0.073 |
| Sex male/female | 94/144 | 93/139 | 0.925 |
| Clinical characteristics a | |||
| Platelets (G/L) | 769 (452–2530) | 754 (450–2490) | 0.539 |
| Hemoglobin g/dl | 14.2 (8.6–17.3) | 14.4 (8.6–17.3) | 0.826 |
| Hematocrit (%) | 42.9 (42.9–52.0) | 42.7 (29.9–52.6) | 0.630 |
| WBC (G/L) | 9.4 (2.21–31.32) | 8.82 (2.21–22.3) | 0.057 |
| LDH (U/L) | 221 (118–763) | 207 (104–763) | <0.001 |
| Palpable splenomegaly (218/238)b | 16.4% (39) | 11.9% (26) | 0.183 |
| Fibrosis grading ⩾1 | 8.4% (20) | 0.0% (0) | <0.001 |
| Molecular characteristics | |||
| Pathogenetic mutation present (238/169)b | 100% (238) | 72.8% (169) | – |
| JAK2 V617F (238/220)b | 72.7% (173) | 80.5% (136) | 0.078 |
| CALR (181/141)b | 24.4% (58) | 16.0% (27) | 0.048 |
| MPL (75/53)b | 2.9% (7) | 3.5% (6) | 0.780 |
| Symptoms at diagnosis | |||
| Constitutional symptoms (200/169)b | 16.0% (32) | 14.8% (25) | 0.774 |
| Weight loss | 4.5% (9) | 4.1% (7) | 1.000 |
| Night sweats | 8.5% (17) | 8.3% (14) | 1.000 |
| Fatigue | 5.0% (10) | 5.9% (10) | 0.818 |
| Pruritus (202/175)b | 2.0% (4) | 2.3% (4) | 1.000 |
| Cytoreductive therapy (191/164) b | |||
| Hydroxurea | 42.9% (82) | 42.1% (69) | 0.494 |
| Interferon-alpha | 34.6% (66) | 30.5% (50) | 0.429 |
| Anagrelide | 30.4% (58) | 34.1% (56) | 0.494 |
| JAK1/2-Inhibitor | 4.7% (9) | 3.0% (5) | 0.586 |
| Busulfan | 2.6% (5) | 2.4% (4) | 1.000 |
| Othersc | 4.2% (8) | 0.6% (1) | 0.042 |
| Antithrombotic therapy with low-dose aspirin (189/160)b | 90.5% (171) | 88.8% (142) | 0.602 |
Abbreviations: WBC, white blood cell count; LDH, serum lactate dehydrogenase.
aMedian, range.
bNumber evaluable in each cohort.
cPipobroman, P32 and other cytoreductive agents.
Table 4.
Clinical characteristics of patients with WHO-defined essential thrombocythemia (ET) compared with WHO-defined prefibrotic primary myelofibrosis (prePMF) at presentation as derived from the BCSH-confirmed ET cohort
| WHO-defined ET 3 | WHO-defined prePMF 3 | P-value | |
|---|---|---|---|
| General characteristics | |||
| n | 141 | 77 | |
| Age at diagnosis (years) | 58.9 (18.8–88.8) | 64.6 (23.2–88.1) | 0.086 |
| Sex male/female | 58/83 | 27/50 | 0.486 |
| Clinical characteristics a | |||
| Platelets (G/L) | 725 (452–1836) | 840 (457–2530) | 0.012 |
| Hemoglobin (g/dl) | 14.5 (11.5–17.3) | 13.9 (8.6–16.6) | 0.007 |
| Hematocrit (%) | 43.0 (33.2–52.0) | 41.6 (27.5–48.9) | 0.036 |
| WBC (G/L) | 8.8 (2.2–21.1) | 10.3 (4.0–31.3) | 0.004 |
| LDH (U/L) | 209 (110–763) | 270 (136–598) | <0.001 |
| Palpable splenomegaly (141/77)b | 9.9% (14) | 23.4% (18) | 0.009 |
| Fibrosis grading ⩾1 | 0.0% (0) | 20.8% (16) | <0.001 |
| Molecular characteristics | |||
| Pathogenetic mutation present (141/77)b | 100% (141) | 100% (77) | – |
| JAK2 V617F (141/77)b | 78.0% (110) | 61.0% (47) | 0.011 |
| CALR (99/65)b | 19.2% (27) | 35.1% (27) | 0.013 |
| MPL (33/37)b | 2.8% (4) | 3.9% (3) | 0.700 |
| Symptoms at diagnosis | |||
| Constitutional symptoms (111/71)b | 15.8% (16) | 20.3% (10) | 1.000 |
| Weight loss | 3.6% (4) | 7.0% (5) | 0.315 |
| Night sweats | 8.1% (9) | 4.2% (3) | 0.372 |
| Fatigue | 5.4% (6) | 5.6% (4) | 1.000 |
| Pruritus (111/71)b | 1.8% (2) | 1.4% (1) | 1.000 |
| Cytoreductive therapy (108/63) b | |||
| Hydroxyurea | 45.4% (49) | 38.1% (24) | 0.423 |
| Interferon-alpha | 31.5% (34) | 34.9% (22) | 0.736 |
| Anagrelide | 33.3% (36) | 28.6% (18) | 0.610 |
| JAK1/2-Inhibitor | 4.6% (5) | 6.3% (4) | 0.727 |
| Busulfan | 1.9% (2) | 3.2% (2) | 0.626 |
| Othersc | 0.9% (1) | 6.3% (4) | 0.062 |
| Antithrombotic therapy with low-dose aspirin (106/63)b | 89.6% (95) | 88.9% (56) | 1.000 |
Abbreviations: WBC, white blood cell count; LDH, serum lactate dehydrogenase.
aMedian, range.
bNumber evaluable in each cohort.
cPipobroman, P32 and other cytoreductive agents.
Further the authors confirmed that the last sentence of the third to last paragraph of the methods section should be amended to read ‘Antithrombotic therapy with low-dose aspirin was applied in 142 patients of the WHO-confirmed ET and 171 patients of the BCSH-defined ET cohort.’
The authors wish to apologize for any inconvenience caused.
Footnotes
The online version of the original article can be found at 10.1038/leu.2015.360